Mehrizi Akram Abouie, Zakeri Sedigheh, Salmanian Ali-Hatef, Sanati Mohammad Hossein, Djadid Navid Dinparast
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Acta Trop. 2009 Oct;112(1):1-7. doi: 10.1016/j.actatropica.2009.05.016. Epub 2009 May 29.
The C-terminal region of Plasmodium vivax merozoite surface protein 1 (PvMSP-1(19)) is a leading vaccine candidate for inclusion in a polyvalent malaria vaccine. In the present study, the IgG subclasses profile and the avidity of IgG to PvMSP-1(19) were evaluated in individuals (n=94) naturally exposed to P. vivax parasite in malaria endemic areas in Chabahar districts, Iran. In individuals with patent P. vivax malaria, 86.1% was sero-positive to PvMSP-1(19) and IgG1 (81.9%) was the predominant subclass. In addition, to determine the persistence of specific IgG, IgG1 and IgG3 antibodies to PvMSP-1(19), the frequency of antibodies was determined in the infected subjects (n=74) after treatment with standard chloroquine and it was detected that the frequency of responders was significantly reduced to 51.3%, 51% and 16.2%, respectively. The antigen-binding avidity of IgG antibodies to PvMSP-1(19) was measured in sero-positive sera and the high-avidity of IgG, IgG1 and IgG3 was found in 66.6%, 61% and 47% of the infected subjects with P. vivax, respectively. The present result shows that individuals who exposed to vivax malaria in the endemic region in Iran develop antibodies with high-avidity to PvMSP-1(19). These results could help to understand the interactions between the host and P. vivax parasite in development of MSP-1(19)-based vaccine.
间日疟原虫裂殖子表面蛋白1(PvMSP - 1(19))的C末端区域是多价疟疾疫苗中的主要候选疫苗。在本研究中,对伊朗恰巴哈尔地区疟疾流行区自然暴露于间日疟原虫的个体(n = 94)的IgG亚类谱以及IgG对PvMSP - 1(19)的亲和力进行了评估。在患有间日疟现症疟疾的个体中,86.1%对PvMSP - 1(19)呈血清阳性,且IgG1(81.9%)是主要亚类。此外,为了确定针对PvMSP - 1(19)的特异性IgG、IgG1和IgG3抗体的持久性,在用标准氯喹治疗后的感染受试者(n = 74)中测定了抗体频率,结果发现应答者的频率分别显著降至51.3%、51%和16.2%。在血清阳性血清中测量了IgG抗体对PvMSP - 1(19)的抗原结合亲和力,发现间日疟感染受试者中分别有66.6%、61%和47%的IgG、IgG1和IgG3具有高亲和力。目前的结果表明,在伊朗流行区暴露于间日疟的个体产生了对PvMSP - 1(19)具有高亲和力的抗体。这些结果有助于理解在基于MSP - 1(19)的疫苗开发中宿主与间日疟原虫之间的相互作用。